Tech Company M&A Transactions
Counsyl Acquisition
Counsyl, operating out of San Francisco, was acquired by Myriad Genetics. The transaction price was $375 million.
Transaction Overview
Company Name
Acquired By
Announced On
5/29/2018
Transaction Type
M&A
Amount
$375,000,000
M&A Terms
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non-invasive prenatal screening for $375 million through a combination of cash and Myriad common stock.
Company Information
Company Status
Acquired or Merged
Industry
Medical Devices & Instruments
Mailing Address
180 Kimball Way
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Counsyl is a health technology company that offers DNA screening for men, women, and their children. We help you make smart choices about your health, your family, and your future.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ramji Srinivasan
Chief Financial Officer
Joel Jung
Chief Medical Officer
James Goldberg
Chief Scientific Officer
Eric Evans
VP - General Counsel
Peter Soparkar
VP - Operations
John Tan
VP - Product Management
Rishi Kacker
Browse more venture capital transactions:
Prev: 5/29/2018: DCC venture capital transaction
Next: 5/30/2018: Precision NanoSystems venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs